Probiotics combined with aminosalicylic acid affiliates remission of ulcerative colitis: a meta-analysis of randomized controlled trial

Abstract

We conducted a meta-analysis to evaluate the effect of probiotic combined with aminosalicylic on induction remission maintenance treatment of ulcerative colitis. We conducted systematic searches in several Chinses and English databases from inception to June 2018, screening randomized controlled trial about effect of probiotics combined with aminosalicylic acid on ulcerative colitis. The evaluation indicator was the rate of remission. The relative risk (RR) and 95% confidence interval (CI) were calculated. A total of twenty-seven studies with 1942 patients were included. The results indicated that the remission rate was significantly higher in the group using probiotics combined with aminosalicylic acid than that in the group using aminosalicylic acid alone (RR=1.40, 95%CI: 1.27-1.53, =0.000). The subgroup analysis indicated that probiotics combined with aminosalicylic acid can significantly elevate the remission rate in both mild to moderate (RR=1.33, 95%CI: 1.16-1.54, =0.000) and active stage (RR=1.40, 95%CI: 1.27-1.64, =0.000) ulcerative colitis. In different number of bacterium, drug types, treatment period, the combination with probiotics can significantly increase the remission rate ulcerative colitis. The funnel plot shown slight publication bias. Probiotics in conjunction with aminosalicylic can obviously increase the clinical remission rate of activity ulcerative colitis than drug alone. There was no significant difference between combined with mesalazine and salicylazosulfapyridine.

The Efficacy and Safety of Mesalamine and Probiotics in Mild‐to‐Moderate Ulcerative Colitis: A Systematic Review and Meta‐Analysis

“…(3) to regulate the mucosal immune response; and (4) to reduce the secretion of proinflammatory factors [46]. erefore, if probiotics was used when mesalamine was taken, the treatment plan would regulate the intestinal flora, curb the inflammatory responses, and improve therapeutic efficacy [46].…”

“…(3) to regulate the mucosal immune response; and (4) to reduce the secretion of proinflammatory factors [46]. erefore, if probiotics was used when mesalamine was taken, the treatment plan would regulate the intestinal flora, curb the inflammatory responses, and improve therapeutic efficacy [46]. Furthermore, the advantages of probiotics therapy include overcoming gastrointestinal tract infections, resisting stomach acid, bile, and antibiotics, and modifying immune processes to destroy invading microorganisms [47].…”

Enteral Nutrition Supplemented with Transforming Growth Factor-β, Colostrum, Probiotics, and Other Nutritional Compounds in the Treatment of Patients with Inflammatory Bowel Disease

“…There were six metanalyses published during the last two years [13,[69][70][71][72][73], the results of which are summarized in Table 4. The conclusions that we can draw from these metaanalyses could be the following: The administration of probiotics either alone or in combination with mesalazine could increase the rate of clinical remission of patients with UC.…”

Discovery of a Novel Multi-Strains Probiotic Formulation with Improved Efficacy toward Intestinal Inflammation

“…Furthermore, novel live biotherapeutics, among which several putative beneficial bacteria including Clostridium, Firmicutes spores, Bacteroides and Roseburia isolated from healthy human microbiota are currently investigated [ 54 ]. Analyses of randomized clinical trials with various probiotic formulations have demonstrated that single strain probiotics exert beneficial effects over placebos in UC patients [ 55 ] and that beneficial effects were maintained also when the probiotics were associated with anti-inflammatory agents such as 5-aminosalicycilic acid [ 56 ]. Multiple strains formulations have been demonstrated effective in UC and pouchitis.…”